Toxicity profile and objective response of paclitaxel in metastatic breast cancer

Journal of the College of Physicians and Surgeons Pakistan

Volumn 15, Issue 4, 2005, Pages 200-203

  Ansari, Tariq Nadeem ^b   Mahmood, Ahsan ^b   Khattak, Badshah Khan ^a   Rasul, Shahid ^b   Syed, Abdus Samad ^b  

^a National Institute of Heart Diseases National University of Medical Sciences   (Pakistan)

^b Malir National University of Medical Sciences   (Pakistan)

Author keywords

Breast cancer; Metastatic; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TROPISETRON;

ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; HISTOPATHOLOGY; HOSPITAL DEPARTMENT; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALAISE; MYALGIA; NAUSEA; NEUTROPENIA; ONCOLOGY; PAKISTAN; PHASE 2 CLINICAL TRIAL; PUBLIC HOSPITAL; SOFT TISSUE METASTASIS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PAKISTAN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 18744377541     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, et al. Doxorubicin and Paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707-15.
2. Henderson IC. Chemotherapy for metastatic disease, In: Harris JR, Hellmann S, Henderson IC, (edi). Breast diseases. 2nd ed. Philadelphia. Lippincott 1991; 604-65.
3. Kornek GV, Ulrich - Pur H, Penz M, Haider K, Kwasny W, Depisch D, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001; 19: 621-7.
4. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31510 women. J Clin Oncol 1998; 16: 3439-60.
5. Nabholtz JM, Mackey JR, Smylie M, Paterson A, Noel DR, Al-Tweigeri T, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001; 19: 314-21.
6. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-1805.
7. Reichman BS, Seidman AD, Crown JP, Heclan R, Hakes TB, Lebwohl DE, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943-51.
8. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332: 1004-14.
9. Gelmon K, Nabholtz JM, Bontenbal M. Randomized trial of two doses of Paclitaxel in metastatic breast cancer after failure of standard therapy. (abstract 493) In: 8th NCI EORTC symposium on new drugs in cancer therapy. Amsterdam: The Netherlands, 1994 March 15-18; 5(suppl 5): 198.
10. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 3353-61.
11. French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000; 18: 3115-24.
12. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19: 4216-23.